Redefining cardiometabolic aging.

Redefining cardiometabolic aging.

Zoe Biosciences is developing best-in-class therapies to treat cardiometabolic disease.

Zoe Biosciences is developing best-in-class therapies to treat cardiometabolic disease.

Introduction

We are built upon decades of combined PAI-1 and APJ research with target validation across preclinical, epidemiological, and epigenetic indices.

Cardiometabolic aging is a defining challenge of our time.

32%

Of all global deaths

Are due to cardiovascular diseases

> 1/3

U.S. adults

Have prediabetes. Most don't know they have it

$418B

USD

Annual cost of CVD to the US economy

We are a team of drug discovery and translational experts